Alerts will be sent to your verified email
Verify EmailSTAR
Strides Pharma Scien
|
FDC
|
Unichem Lab
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
260.0 . | n/a | 41.0 . |
Number of ANDA's Approved By USFDA
|
245.0 . | n/a | 27.0 . |
R&D as a % of Total Sales
|
1.82 % | 2.06 % | 7.38 % |
Financials
|
|||
5 yr Average ROE
|
-4.18 % | 13.66 % | -2.21 % |
5yr average Equity Multiplier
|
2.64 | 1.57 | 1.28 |
5yr Average Asset Turnover Ratio
|
0.54 | 0.54 | 0.42 |
5yr Avg Net Profit Margin
|
-2.56 % | 16.24 % | -3.85 % |
Price to Book
|
2.76 | 3.03 | 1.88 |
P/E
|
23.28 | 25.31 | 0.0 |
5yr Avg Cash Conversion Cycle
|
-66.38 Days | -14.0 Days | 80.33 Days |
Inventory Days
|
69.16 Days | 59.23 Days | 146.44 Days |
Days Receivable
|
71.28 Days | 21.91 Days | 128.35 Days |
Days Payable
|
248.23 Days | 86.54 Days | 225.53 Days |
5yr Average Interest Coverage Ratio
|
0.41 | 93.3 | -0.08 |
5yr Avg ROCE
|
9.77 % | 14.95 % | -0.47 % |
5yr Avg Operating Profit Margin
|
13.1 % | 18.97 % | 2.2 % |
5 yr average Debt to Equity
|
1.02 | 0.0 | 0.09 |
5yr CAGR Net Profit
|
n/a | 4.94 % | 3.21 % |
5yr Average Return on Assets
|
-1.34 % | 8.73 % | -1.68 % |
Shareholdings
|
|||
Promoter Holding
|
28.3 % | 69.66 % | 70.22 % |
Share Pledged by Promoters
|
51.98 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-2.3 % | 0.3 % | 19.29 % |
Change in Mutual Fund Holding (3 Yrs)
|
-3.5 % | 0.49 % | 1.71 % |
Strides Pharma Scien
|
FDC
|
Unichem Lab
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Customer Segment
|
Customer Segment
|
-
|
-
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|